Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Buy" by Brokerages

Key Points

• Analysts maintain a consensus “Buy” rating on Immuneering, with four buy ratings, two strong-buy ratings, and one sell rating. The average 12-month price target is $17.50, substantially above the stock’s reported $4.27 price.
• Immuneering reported a quarterly loss of $0.27 per share, slightly missing the consensus estimate of a $0.26 loss. Analysts expect a full-year loss of approximately $1.09 per share.
• Institutional investors and hedge funds own 67.65% of the company, while Immuneering’s lead candidate, IRX-2, is advancing through Phase 2 trials for painful diabetic peripheral neuropathy.

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have been given a consensus recommendation of "Buy" by the seven brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $17.50.

Several analysts recently commented on IMRX shares. Oppenheimer reiterated an "outperform" rating on shares of Immuneering in a research report on Monday, June 1st. UBS Group set a $14.00 price objective on Immuneering in a report on Thursday, August 6th. Needham & Company LLC lifted their target price on shares of Immuneering from $11.00 to $18.00 and gave the stock a "buy" rating in a research note on Monday, July 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immuneering in a report on Wednesday, June 24th. Finally, Cantor Fitzgerald began coverage on shares of Immuneering in a research report on Wednesday, July 8th. They issued an "overweight" rating and a $17.00 target price for the company.

Immuneering Price Performance

IMRX opened at $4.27 on Monday. The company has a market cap of $276.27 million, a PE ratio of -4.11 and a beta of 0.40. Immuneering has a twelve month low of $3.86 and a twelve month high of $10.08. The company has a 50-day moving average price of $4.81 and a 200 day moving average price of $4.98.

Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.01). As a group, sell-side analysts expect that Immuneering will post -1.09 earnings per share for the current year.

Institutional Trading of Immuneering

A number of hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new position in Immuneering in the 4th quarter worth approximately $33,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Immuneering in the second quarter valued at approximately $34,000. Levin Capital Strategies L.P. purchased a new position in Immuneering during the first quarter worth approximately $53,000. Mercer Global Advisors Inc. ADV purchased a new position in Immuneering during the third quarter worth approximately $70,000. Finally, SummitTX Capital L.P. acquired a new position in Immuneering during the fourth quarter worth $69,000. Institutional investors and hedge funds own 67.65% of the company's stock.

About Immuneering

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.